Sign inCreate account

Report workspace tools

NCT02603068WITHDRAWNanonymous

Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Sponsor

Source record

United Therapeutics

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Pulmonary Hypertension associated with Pulmonary Fibrosis

Indication / condition

AI-normalized

Pulmonary Hypertension

Intervention

Source record

Oral treprostinil

Source & freshness

Source record

NCT ID

NCT02603068

Original source

ClinicalTrials.gov

Source last updated

Feb 09, 2016

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02603068

Title

Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Sponsor

United Therapeutics

Status

WITHDRAWN

Phase

Phase 2

Condition raw

Pulmonary Hypertension

Condition normalized

Pulmonary Hypertension

Modality raw

Pulmonary Hypertension

Modality normalized

small molecule

Target raw

Pulmonary Hypertension associated with Pulmonary Fibrosis

Target normalized

Pulmonary Hypertension associated with Pulmonary Fibrosis

Interventions

Oral treprostinil

Public preview

Source record

This clinical trial aimed to evaluate the safety and efficacy of oral treprostinil in subjects with pulmonary hypertension associated with pulmonary fibrosis. The study was designed as a multicenter, randomized, open-label trial involving at least 10 clinical trial centers and aimed to enroll 52 subjects over a 24-month period.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02603068

Status

WITHDRAWN

Phase

Phase 2

Sponsor

United Therapeutics

Executive brief

Investment-Ready Snapshot

This clinical trial aimed to evaluate the safety and efficacy of oral treprostinil in subjects with pulmonary hypertension associated with pulmonary fibrosis. The study was designed as a multicenter, randomized, open-label trial involving at least 10 clinical trial centers and aimed to enroll 52 subjects over a 24-month period.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 09, 2016
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02603068

Indication

Pulmonary Hypertension

Modality

small molecule

Target

Pulmonary Hypertension associated with Pulmonary Fibrosis

Intervention

Oral treprostinil

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.